Anpario (LSE:ANP) reported a robust trading performance for the year ended 2025, with unaudited revenue increasing 23% year on year to approximately £47.1 million and adjusted EBITDA expected to be at least £9.4 million. Both metrics came in ahead of market expectations, reflecting high operational gearing and broad-based growth across the majority of the group’s geographic markets.
The integration of Bio-Vet, acquired in late 2024, is progressing in line with management’s plans and delivered a strong contribution in the second half of the year. Despite making contingent payments related to the acquisition, Anpario ended the period with a strengthened net cash position of £12.4 million, underlining the resilience of the balance sheet.
Management said the group’s financial position provides flexibility to continue investing in product development, international expansion and further complementary acquisitions. Full-year results are scheduled for release toward the end of March 2026.
From an investment perspective, Anpario’s outlook is supported by its strong financial performance and recent positive corporate developments. Share price technical indicators point to a bullish trend, while valuation appears reasonable given the group’s growth profile. Overall, the company enters 2026 with momentum across both operations and strategy.
More about Anpario
Anpario plc is an independent producer of natural and sustainable animal feed additives designed to improve animal health, nutrition and biosecurity. The group supplies customers worldwide, with key growth markets in Asia, the Americas and Europe, and follows a strategy centred on innovation, global expansion and earnings-enhancing acquisitions, including the purchase of Bio-Vet in 2024.
Leave a Reply